• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

N-Acetylgalactosamine-6-Sulfatase (GALNS) Human Recombinant Protein

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS958562

MBS958562 is a recombinant protein targeting GALNS. Also known as Recombinant Human N-acetylgalactosamine-6-sulfatase. Host: E Coli or Yeast or Baculovirus or Mammalian Cell. More details

$275 / 0.02 mg (E-Coli) +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
N-acetylgalactosamine-6-sulfatase (GALNS), Recombinant Protein
Full Product Name
Recombinant Human N-acetylgalactosamine-6-sulfatase
Product Gene Name
Product Synonym Names
Chondroitinsulfatase; Chondroitinase; Galactose-6-sulfate sulfatase; GalN6S; N-acetylgalactosamine-6-sulfate sulfatase; GalNAc6S sulfatase
Sequence
APQPPNILLL LMDDMGWGDL GVYGEPSRET PNLDRMAAEG LLFPNFYSAN PLCSPSRAAL LTGRLPIRNG FYTTNAHARN AYTPQEIVGG IPDSEQLLPE LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF DEWFGSPNCH FGPYDNKARP NIPVYRDWEM VGRYYEEFPI NLKTGEANLT QIYLQEALDF IKRQARHHPF FLYWAVDATH APVYASKPFL GTSQRGRYGD AVREIDDSIG KILELLQDLH VADNTFVFFT SDNGAALISA PEQGGSNGPF LCGKQTTFEG GMREPALAWW PGHVTAGQVS HQLGSIMDLF TTSLALAGLT PPSDRAIDGL NLLPTLLQGR LMDRPIFYYR GDTLMAATLG QHKAHFWTWT NSWENFRQGI DFCPGQNVSG VTTHNLEDHT KLPLIFHLGR DPGERFPLSF ASAEYQEALS RITSVVQQHQ EALVPAQPQL NVCNWAVMNW APPGCEKLGK CLTPPESIPK KCLWSH
Host
E Coli or Yeast or Baculovirus or Mammalian Cell
Form/Format
Lyophilized or liquid (Format to be determined during the manufacturing process)
Purity/Purification
Greater or equal to 85% purity as determined by SDS-PAGE. (lot specific)
Preparation and Storage
Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.
Molecular Weight
57.4 kDa
Sequence Positions
27-522aa, Full Length of Mature Protein
Tag Information
This protein contains an N-terminal tag and may also contain a C-terminal tag. Tag types are determined by various factors including tag-protein stability, please inquire for tag information.
Sterility
Sterile filter available upon request.
Endotoxin
Low endotoxin available upon request.
OMIM
253000
3D Structure
ModBase 3D Structure for P34059

Product Categories/Family for GALNS recombinant protein

ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.

Product References and Citations for GALNS recombinant protein

Morquio disease isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase.Tomatsu S., Fukuda S., Masue M., Sukegawa K., Fukao T., Yamagishi A., Hori T., Iwata H., Ogawa T., Nakashima Y., Hanyu Y., Hashimoto T., Titani K., Oyama R., Suzuki M., Yagi K., Hayashi Y., Orii T.Biochem. Biophys. Res. Commun. 181:677-683(1991) Morquio A syndrome cloning, sequence, and structure of the human N-acetylgalactosamine 6-sulfatase (GALNS) gene.Morris C.P., Guo X.H., Apostolou S., Hopwood J.J., Scott H.S.Genomics 22:652-654(1994) Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.J. Proteome Res. 8:651-661(2009) The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A.Rivera-Colon Y., Schutsky E.K., Kita A.Z., Garman S.C.J. Mol. Biol. 423:736-751(2012) Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases.Fukuda S., Tomatsu S., Masue M., Sukegawa K., Iwata H., Ogawa T., Nakashima Y., Hori T., Yamagishi A., Hanyu Y., Morooka K., Kiman T., Hashimoto T., Orii T.J. Clin. Invest. 90:1049-1053(1992) Mucopolysaccharidosis IVA identification of a common missense mutation I113F in the N-Acetylgalactosamine-6-sulfate sulfatase gene.Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Maruf Rezvi G., Yamagishi A., Yamada N., Kato Z., Isogai K., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.Am. J. Hum. Genet. 57:556-563(1995) Mucopolysaccharidosis IVA screening and identification of mutations of the N-acetylgalactosamine-6-sulfate sulfatase gene.Ogawa T., Tomatsu S., Fukuda S., Yamagishi A., Maruf Rezvi G., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.Hum. Mol. Genet. 4:341-349(1995) Mucopolysaccharidosis type IVA identification of six novel mutations among non-Japanese patients.Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Maruf Rezvi G., Yamagishi A., Yamada N., Kato Z., Isogai K., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.Hum. Mol. Genet. 4:741-743(1995) Two new mutations, Q473X and N487S, in a Caucasian patient with mucopolysaccharidosis IVA (Morquio disease) .Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Yamada N., Isogai K., Kato Z., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.Hum. Mutat. 6:195-196(1995) Mucopolysaccharidosis IVA four new exonic mutations in patients with N-acetylgalactosamine-6-sulfate sulfatase deficiency.Tomatsu S., Fukuda S., Yamagishi A., Cooper A., Wraith J.E., Hori T., Kato Z., Yamada N., Isogai K., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.Am. J. Hum. Genet. 58:950-962(1996) Heteroallelic missense mutations of the galactosamine-6-sulfate sulfatase (GALNS) gene in a mild form of Morquio disease (MPS IVA) .Cole D.E.C., Fukuda S., Gordon B.A., Rip J.W., Lecouteur A.N., Rupar C.A., Tomatsu S., Ogawa T., Sukegawa K., Orii T.3.3.CO;2-V>Am. J. Med. Genet. 63:558-565(1996) Identification of 31 novel mutations in the N-acetylgalactosamine-6-sulfatase gene reveals excessive allelic heterogeneity among patients with Morquio A syndrome.Bunge S., Kleijer W.J., Tylki-Szymanska A., Steglich C., Beck M., Tomatsu S., Fukuda S., Poorthuis B.J.H.M., Czartoryska B., Orii T., Gal A.3.3.CO;2-M>Hum. Mutat. 10:223-232(1997) Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS gene.Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Ferreira P., di Natale P., Tortora P., Fujimoto A., Kato Z., Yamada N., Isogai K., Yamagishi A., Sukegawa K., Suzuki Y., Shimozawa N., Kondo N., Sly W.S., Orii T.3.0.CO;2-B>Hum. Mutat. 10:368-375(1997) Molecular heterogeneity in mucopolysaccharidosis IVA in Australia and Northern Ireland nine novel mutations including T312S, a common allele that confers a mild phenotype.Yamada N., Fukuda S., Tomatsu S., Muller V., Hopwood J.J., Nelson J., Kato Z., Yamagishi A., Sukegawa K., Kondo N., Orii T.3.0.CO;2-J>Hum. Mutat. 11:202-208(1998) Fifteen polymorphisms in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene diagnostic implications in Morquio disease.Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Yamagishi A., Kato Z., Yamada N., Isogai K., Sukegawa K., Suzuki Y., Shimozawa N., Kondo N., Orii T.Hum. Mutat. Suppl. 1:S42-S46(1998) Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A) .Tomatsu S., Montano A.M., Nishioka T., Gutierrez M.A., Pena O.M., Tranda Firescu G.G., Lopez P., Yamaguchi S., Noguchi A., Orii T.Hum. Mutat. 26:500-512(2005) The consensus coding sequences of human breast and colorectal cancers.Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.Science 314:268-274(2006) Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.Morrone A., Tylee K.L., Al-Sayed M., Brusius-Facchin A.C., Caciotti A., Church H.J., Coll M.J., Davidson K., Fietz M.J., Gort L., Hegde M., Kubaski F., Lacerda L., Laranjeira F., Leistner-Segal S., Mooney S., Pajares S., Pollard L., Ribeiro I., Wang R.Y., Miller N.Mol. Genet. Metab. 112:160-170(2014)

Other Notes

Small volumes of GALNS recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for GALNS. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
N-acetylgalactosamine-6-sulfatase
NCBI Official Synonym Full Names
galactosamine (N-acetyl)-6-sulfatase
NCBI Official Symbol
GALNS
NCBI Official Synonym Symbols
GAS; MPS4A; GalN6S; GALNAC6S
UniProt Protein Name
N-acetylgalactosamine-6-sulfatase
UniProt Synonym Protein Names
Chondroitinsulfatase; Chondroitinase; Galactose-6-sulfate sulfatase; GalN6S; N-acetylgalactosamine-6-sulfate sulfatase; GalNAc6S sulfatase
UniProt Gene Name
GALNS
UniProt Synonym Gene Names
Chondroitinase; GalN6S; GalNAc6S sulfatase
UniProt Entry Name
GALNS_HUMAN
NCBI Protein Information
N-acetylgalactosamine-6-sulfatase

NCBI Summary for GALNS

This gene encodes N-acetylgalactosamine-6-sulfatase which is a lysosomal exohydrolase required for the degradation of the glycosaminoglycans, keratan sulfate, and chondroitin 6-sulfate. Sequence alterations including point, missense and nonsense mutations, as well as those that affect splicing, result in a deficiency of this enzyme. Deficiencies of this enzyme lead to Morquio A syndrome, a lysosomal storage disorder. [provided by RefSeq, Jul 2008]
Show more

UniProt Comments for GALNS

GALNS: Defects in GALNS are the cause of mucopolysaccharidosis type 4A (MPS4A); also known as Morquio A syndrome. MPS4A is a form of mucopolysaccharidosis type 4, an autosomal recessive lysosomal storage disease characterized by intracellular accumulation of keratan sulfate and chondroitin-6-sulfate. Key clinical features include short stature, skeletal dysplasia, dental anomalies, and corneal clouding. Intelligence is normal and there is no direct central nervous system involvement, although the skeletal changes may result in neurologic complications. There is variable severity, but patients with the severe phenotype usually do not survive past the second or third decade of life. Belongs to the sulfatase family.

Protein type: Glycan Metabolism - glycosaminoglycan degradation; Hydrolase; EC 3.1.6.4

Chromosomal Location of Human Ortholog: 16q24.3

Cellular Component: lysosomal lumen

Molecular Function: metal ion binding; N-acetylgalactosamine-4-sulfatase activity; N-acetylgalactosamine-6-sulfatase activity; sulfuric ester hydrolase activity

Biological Process: carbohydrate metabolic process; glycosaminoglycan metabolic process; keratan sulfate catabolic process; keratan sulfate metabolic process

Disease: Mucopolysaccharidosis, Type Iva
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000